lymphocytes

[Blood Advances] Scientists conducted a prospective single-center Phase II trial in which they added autologous anti-CD19 humanized binding domain T cells to ibrutinib in chronic lymphocytic leukemia patients not in complete remission despite at least six months of ibrutinib.

[Signal Transduction and Targeted Therapy] Via an unbiased genome-wide CRISPR/Cas9 screening, scientists identified loss of NOXA, a B-cell lymphoma 2 family protein in B cell malignancies, as a pivotal regulator of resistance to CAR T cell therapy by impairing apoptosis of tumor cells both in vitro and in vivo.

[Nature Biotechnology] By testing immunogenicity with autologous blood lymphocytes from patients with cancer, scientists detected pre-established CD4+ and CD8+ T cell responses for 10 of 21 and for 1 of 30 previously identified gene fusions, respectively.

[eLife] The authors demonstrated that homology cluster analysis of T cell receptor (TCR) repertoires efficiently identified tumor-reactive TCRs.

[US FDA] The FDA approved axicabtagene ciloleucel for adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy.

[Nature Immunology] The authors utilize major histocompatibility complex multimers with single-cell RNA sequencing to profile SARS-CoV-2-responsive T cells ex vivo from humans with one, two or three antigen exposures, including vaccination, primary infection and breakthrough infection.